


CERTIFICATE OF ANALYSIS – TECHNICAL DATA SHEET

Product name	FHR-3, Human, mAb 3.11		
Catalog number	HM2427-20UG		
Lot number	-	Expiry date	-
Volume	200 µL	Amount	20 µg
Formulation	0.2 µm filtered in PBS+0.02%NaN3+0.1%BSA	Concentration	100 µg/ml
Host Species	Mouse IgG1	Conjugate	None
Endotoxin	N/A	Purification	Protein G
Storage	4°C		

Application notes

	IHC-F	IHC-P	IF	FC	FS	IA	IP	W
Reference #								-
Yes								•
No								
N.D.	•	•	•	•	•	•	•	

N.D.= Not Determined; IHC = Immuno histochemistry; F = Frozen sections; P = Paraffin sections; IF = Immuno Fluorescence; FC = Flow Cytometry; FS = Functional Studies; IA = Immuno Assays; IP = Immuno Precipitation; W = Western blot



W: Western blot analysis performed with human FHR-3 protein with antibody 3.11 (HM2427) at 2 µg/ml.

Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

- W: A non-reduced and/or reduced sample treatment and SDS-Page was used. The band sizes around ~36-56 kDa.

General Information

Description	HM2427 (anti-FHR-3; clone 3.11) is a mouse monoclonal antibody recognizing human full length Complement Factor H-related protein 3 (FHR-3), a glycoprotein that belongs to the complement regulatory protein family. FHR-3 is synthesized and secreted primarily by the liver but also by immune cells such as monocytes, macrophages, and dendritic cells. It is present in plasma in various glycosylated forms ranging from 35 to 56 kDa. Structurally, FHR-3 shares homology with Complement Factor H (CFH), a pivotal regulator within the complement system. Also FHR-3 operates as part of the complement regulatory network, contributing to control of the complement cascade but its precise function is poorly characterized. FHR-3 predominantly exerts its regulatory influence within the alternative pathway (AP) of the complement system. Weak cofactor activity and an enhancement of the FH cofactor activity were reported, and also a marginal inhibitory effect was observed in hemolytic assays using FH depleted serum. However, these results need to be confirmed in independent studies. Disruptions in FHR-3 expression or function have been linked to specific diseases. For instance, imbalances in FHR-3 levels or activities have been associated with conditions like atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD) and systemic lupus erythematosus (SLE). In these disorders, aberrant complement activation and deposition on self-tissues can contribute to pathological processes. FHR-3's involvement in the alternative pathway positions it as a potential therapeutic target for interventions aimed at modulating complement-driven diseases. The participation of FHR-3 in the AP suggests its potential as a therapeutic target for interventions aimed at controlling diseases driven by complement dysregulation.		
Immunogen	Human Complement factor H-related protein 3		
Aliases	CFHL3, CFHR3		
Gene	Gene name: CFHR3	Entrez Gene ID: 10878	Uniprot: Q02985
Storage&stability	Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.		
Precautions	For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.		

We hereby certify that the above-stated information is correct and that this product has been successfully tested by the Quality Control Department. This product was released for sale according to the existing specifications. This document has been produced electronically and is valid without a signature.

Approved by Manager of QC

Date

Do you have any questions or comments regarding this product? Please contact us via support@hycultbiotech.com.